Mouse Models of Corneal Wound Healing in the MICRON Literature

About the MICRON Research Literature

These research pages organize published studies using MICRON imaging systems by animal species and the disease or condition investigated.

All publication counts and figures reflect the complete indexed research collection.

Explore related studies through the MICRON Research Hubs or search the complete publication collection in the reSEARCH portal.

Understanding Corneal Wound Healing

Corneal wound healing is a repair process rather than a disease entity: it is how a transparent, normally avascular and densely innervated tissue responds to injury, through:

  • Epithelial migration and resurfacing
  • A stromal keratocyte and fibroblast response
  • Remodeling of extracellular matrix
  • Regrowth of severed nerves

It is studied because repair can stall or fail, as in persistent epithelial defects and in neurotrophic disease where sensory innervation is lost, and because how the stroma rebuilds decides whether the tissue regains transparency.

Repair ends anywhere between restored clarity and residual opacity, and the literature draws the line between this process and its scarring outcome in more than one place.

Corneal Wound Healing in Experimental Research

What an animal model of corneal wound healing supplies is a controlled injury: the agent, depth, area and moment of wounding are set by the experimenter, so re-epithelialization and the phases that follow can be measured from a known time zero, followed in the same eye, and compared between genotypes, systemic conditions and treatments.

Injury models in this field reach different depths and provoke different repair, spanning:

  • Mechanical epithelial debridement
  • Chemical burn with alkali or vesicant agents
  • Radiation injury
  • Infection

What is being repaired is part of what a given model specifies.

What a controlled injury does not supply is the variability of human injury itself, where agent, depth, extent, contamination and the delay before treatment are encountered rather than chosen. Symptoms such as pain and blurred vision, which are part of how the human condition presents and is judged, lack a direct counterpart in an animal.

Mouse Models of Corneal Wound Healing

The mouse carries most of this work.

Transgenic and knockout lines allow a pathway to be removed or overexpressed, and cost, availability, short generation time and a large body of background data reinforce the choice.

A genetic manipulation constrains rather than isolates a mechanism: developmental compensation and pleiotropy remain possible.

Published MICRON Research: Corneal Wound Healing in Mice

This page lists 17 papers from the MICRON literature, published 2013 to 2026, that study corneal wound healing in mice.

Of these publications:

  • 17 studies used mice as the primary corneal wound healing disease model.

Scope of the literature collection: Publication counts reflect studies identified and indexed in the MICRON research corpus. This collection is not intended to represent an exhaustive review of all published corneal wound healing research.

Which imaging and experimental techniques are used in these studies?

Technique counts are paper-level co-occurrences and do not necessarily indicate that a technique was applied to the focal species or focal disease model.

Capabilities and Limitations of Imaging Techniques

A summary of what each imaging technique listed above can measure, the information it provides, and its limitations in research applications.

Optical Coherence Tomography

Optical coherence tomography provides high-resolution, cross-sectional images of ocular tissues in the living eye, allowing researchers to visualize structures at different depths. OCT is particularly useful for measuring tissue thickness, identifying structural abnormalities, and assessing the location and extent of tissue changes.

As a non-invasive imaging technique, OCT enables repeated measurements in the same eye over time, supporting longitudinal studies of disease progression and treatment response. Although OCT provides detailed structural information, it does not directly measure cellular activity or visual function. Tissue that appears structurally normal may still have functional abnormalities, making OCT a valuable companion to functional assessments such as electroretinography (ERG).

Topical Ophthalmic Drug Delivery

A compound applied as drops to the ocular surface. It is non-invasive and repeatable, so it supports frequent dosing without a procedure for each dose. What the route has to establish depends on the target: for an ocular-surface target, residence time and penetration into the surface tissue are the main barriers; for an intraocular anterior-segment target, the compound must cross ocular-surface and corneal or conjunctival barriers and reach an intraocular concentration sufficient for the experiment; for a posterior-segment target, additional ocular barriers separate the surface from the target and posterior-segment exposure is harder to establish.

Intravitreal Injection / Delivery

Injection into the vitreous places a substance directly into the vitreous at a known administered dose and chosen time, reducing but not eliminating systemic exposure. The injectate may be a therapeutic compound, cell preparation or viral vector, or an agent used to create the model, such as a toxin, vasoactive or excitotoxic compound, or infectious inoculum. The route bypasses surface-delivery barriers and provides direct access to the vitreous and posterior segment, but the concentration reached in a particular ocular tissue depends on distribution and clearance and is not fixed by the injected dose alone. It is invasive and discrete: each repeat dose or challenge requires another injection, and vehicle- or sham-injected controls can help separate effects of the injectate from effects of the procedure.

Fundus Fluorescein Angiography

Fundus fluorescein angiography uses an injected fluorescent dye to visualize blood flow through the retinal and choroidal circulation. Sequential images show how vessels fill, identify areas of reduced or absent perfusion, and reveal dye leakage associated with vascular abnormalities.

This technique is particularly useful for evaluating vascular perfusion, blood-retinal barrier integrity, and abnormal vessel growth. Fluorescein angiography primarily shows dye distribution rather than the surrounding retinal tissue. It provides a two-dimensional (en face) view in which vessels at different depths may overlap. Cross-sectional and cellular structural details require other imaging methods, such as optical coherence tomography (OCT) or optical coherence tomography angiography (OCT-A). Vascular abnormalities that do not affect dye filling or produce leakage may also remain undetected.

Laser Photocoagulation Models

A laser lesion provokes a reproducible, quantifiable injury at a known time and place. Wavelength, power, duration, spot size, pulse mode, focus and lesion location together determine the injury produced, allowing laser exposure to be configured for different experimental endpoints. It is an induced injury, not the disease: it produces a lesion directly, bypassing the process that gives rise to comparable damage in patients.

Electroretinography

Records the retina's electrical response to light, giving component-sensitive information about outer- and inner-retinal function. It measures function directly, which no structural method does. Full-field ERG sums across the whole retina, so a small lesion can leave the trace unchanged; focal and multifocal variants trade signal amplitude for spatial resolution.

Ocular Implants / Sustained Release

A sustained-release system holds a compound in or on the eye and lets it out gradually, so exposure is maintained from one placement rather than from a series of doses. The class spans polymer and non-polymer solid depots, injectable and particulate carriers, and reservoir devices; the release period belongs to the platform and not to the route, and runs from days to years. What the approach is for is to separate the dosing interval from the procedure interval, holding exposure at the target for as long as the question runs, whether that is the few weeks of a short-lived model or the span of a lifelong disease, without an intervention for each dose. What it gives up is control after placement. The release profile has to be measured rather than assumed, altering or ending delivery may require a further procedure, biodegradable systems behave differently from removable ones, and the carrier sits in contact with ocular tissue, so how the eye tolerates it is part of the result and not a precondition of it.

Which MICRON systems and add-ons appear?

Which MICRON systems and add-ons appear?
Instrument Papers
MICRON IV 9
Anterior Segment Imaging System 7
MICRON III 7
Image-Guided OCT 4
Image-Guided Laser 1
Insight Software 1
MICRON (Unspecified) 1

Which strains and genetic lines are used?

Which strains and genetic lines are used?
Strain Papers Reported as
C57BL/6J 8
C57BL/6 4
129S1/SvImJ 2
BALB/c 2
C57B6/6J 1

What other conditions are recorded on the same papers?

What other conditions are recorded on the same papers?
Disease Papers
Corneal Neovascularization 9
Corneal Opacity / Scarring 7
Limbal Stem Cell Deficiency 4
Choroidal Neovascularization 2
Age-Related Macular Degeneration (General) 1
Age-Related Macular Degeneration (Wet/Neovascular) 1
Aniridia 1
Cataract (General) 1
Diabetes Mellitus, Type 1 1
Diabetes Mellitus, Type 2 1
Fungal Keratitis 1
Keratitis (General) 1
Retinal Neovascularization (General) 1
Retinopathy of Prematurity 1

Which MICRON configurations appear in this work?

Configurations recorded in these papers, and the techniques recorded alongside them.

Which MICRON configurations appear in this work?
MICRON configuration Papers Most frequent techniques recorded alongside
MICRON IV 9 Optical Coherence Tomography (4), Topical Ophthalmic Drug Delivery (3), Intravitreal Injection / Delivery (2)
Anterior Segment Imaging System 7 Topical Ophthalmic Drug Delivery (5), Optical Coherence Tomography (3), Electroretinography (1)
MICRON III 7 Topical Ophthalmic Drug Delivery (5), Optical Coherence Tomography (3), Fundus Fluorescein Angiography (1)
Image-Guided OCT 4 Optical Coherence Tomography (3)
Image-Guided Laser 1 Fundus Fluorescein Angiography (1), Intravitreal Injection / Delivery (1), Laser Photocoagulation Models (1)
Insight Software 1 Optical Coherence Tomography (1)
MICRON (Unspecified) 1 Optical Coherence Tomography (1)

The papers

The papers
Year Title Journal Role of focal species MICRON products Links
2026 Targeting Mitochondrial Dysfunction with Mdivi-1 Confers Therapeutic Protection in a Mouse Model of Mustard Keratopathy bioRxiv Disease model Anterior Segment Imaging System, MICRON IV DOI · reSEARCH
2026 Perturbation of epithelial and limbal stem cell identity in a mouse model of pathologic corneal neovascularization Communications Biology Disease model Anterior Segment Imaging System, MICRON III DOI · reSEARCH
2026 Gellan Gum Fluid Gel System for Controlled‐Delivery of Cytokine‐Licensed MSC‐EVs to Enhance Corneal Repair in Limbal Stem Cell Deficiency Advanced Healthcare Materials Disease model Anterior Segment Imaging System, MICRON III DOI · reSEARCH
2026 DKK1 Targeting in Corneal Schwann Cells Rescues Axonal Regeneration and Mechanosensory Function After Corneal Injury. Journal of Neuroscience Research Disease model Anterior Segment Imaging System, MICRON III DOI · reSEARCH
2025 Central Corneal Epithelial Wounding Accelerates Aniridia-Associated Keratopathy in PAX6-Deficient Mice. Investigative Ophthalmology & Visual Science Disease model Anterior Segment Imaging System, MICRON III DOI · reSEARCH
2025 A deep dive into radiation keratopathy; Going beyond the current frontierss. Experimental Eye Research Disease model Image-Guided OCT, MICRON (Unspecified) DOI · reSEARCH
2025 Exploring the Therapeutic Potential of Salivary Exosomes in Corneal Epithelial Wound Healing. Investigative Ophthalmology & Visual Science Disease model MICRON IV DOI · reSEARCH
2025 Zeb1 Facilitates Nitrogen Mustard-Induced Corneal Epithelial Wound Healing by Maintaining Epithelial Renewability. Investigative Ophthalmology & Visual Science Disease model MICRON IV DOI · reSEARCH
2024 Development and characterization of a preclinical mouse model of alkali-induced limbal stem cell deficiency. The Ocular Surface Disease model Anterior Segment Imaging System, Image-Guided OCT, MICRON IV DOI · reSEARCH
2024 A Multifunctional Nanodrug Co-Delivering VEGF-siRNA and Dexamethasone for Synergistic Therapy in Ocular Neovascular Diseases. International Journal of Nanomedicine Disease model MICRON IV DOI · reSEARCH
2024 The mammalian Ire1 inhibitor, 4µ8C, exhibits broad anti-Aspergillus activity in vitro and in a treatment model of fungal keratitis. Frontiers in Cellular and Infection Microbiology Disease model Anterior Segment Imaging System, MICRON IV DOI · reSEARCH
2023 NBL1 Reduces Corneal Fibrosis and Scar Formation after Wounding. Biomolecules Disease model Image-Guided OCT, Insight Software, MICRON IV DOI · reSEARCH
2023 Peroxisome proliferator-activated receptor-α (PPARα) regulates wound healing and mitochondrial metabolism in the cornea. Proceedings of the National Academy of Sciences of the United States of America Disease model MICRON IV DOI · reSEARCH
2022 Plasticity of ocular surface epithelia: Using a murine model of limbal stem cell deficiency to delineate metaplasia and transdifferentiation. Stem Cell Reports Disease model Image-Guided OCT, MICRON IV DOI · reSEARCH
2022 Perfluorodecalin-based oxygenated emulsion as a topical treatment for chemical burn to the eye. Nature Communications Disease model MICRON III DOI · reSEARCH
2022 Topical Nanoemulsion of a Runt-related Transcription Factor 1 Inhibitor for the Treatment of Pathologic Ocular Angiogenesis. Ophthalmology Science Disease model Image-Guided Laser, MICRON III DOI · reSEARCH
2013 Corneal wound healing is compromised by immunoproteasome deficiency. PLoS ONE Disease model MICRON III DOI · reSEARCH

Browse all hubs at MICRON Research Hubs. The full corpus is searchable in the reSEARCH portal.

Last built 2026-11-10 from content tag hubs-content-2026-11-10 (ae06cfc); fact-sheet run sheets-20261110T111119Z. About these hubs Back to top